Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
Type 1 Diabetes
Interventions
DEVICE

t:slim X2 insulin pump with Control-IQ technology 1.5

t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.

Trial Locations (13)

10029

Icahn School of Medicine at Mt. Sinai, New York

22903

University of Virginia, Charlottesville

32610

University of Florida, Gainesville

33612

University of South Florida Diabetes Center, Tampa

46202

Indiana University / Riley Hospital for Children, Indianapolis

50265

Iowa Diabetes and Endocrinology Research Center (IDERC), West Des Moines

60208

Northwestern University, Evanston

64108

Children's Mercy Hospital, Kansas City

78229

Diabetes & Glandular Disease (DGD), San Antonio

80045

Barbara Davis Center, Aurora

92868

Children's Hospital Orange County, Orange

94304

Stanford University, Palo Alto

02215

Joslin Diabetes Center, Boston

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Jaeb Center for Health Research

OTHER

lead

Tandem Diabetes Care, Inc.

INDUSTRY